Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats

Ayşe Gül Kebapçılar, Ayse G Kebapcilar, Kebapcilar AG, ILHAN TT, Tolgay Tuyan Ilhan, Tolgay T Ilhan, Duygu Dursunoglu, Dursunoglu D, Duygu Dursunoğlu, Levent Kebapçılar, Kebapcilar L, Levent Kebapcilar, Süleyman Hilmi İpekçi, Suleyman H Ipekci, Suleyman Baldane, Süleyman Baldane, Ucar MG, Mustafa Gazi Uçar, Mustafa G Ucar, Cem Onur Kıraç, Cem O Kirac, Kurt K, Kübra Kurt, Kubra Kurt, Cetin Celik, Çetin Çeli̇k, Celik C
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2017 · vol. 33(12) , pp. 923–927 · doi:10.1080/09513590.2017.1320384 · PMID:28452240 · W2610096835
Other OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

Oral rosuvastatin and intraperitoneal bevacizumab significantly reduced surgically induced endometriotic implants in rats compared to oral progesterone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This study hypothesizes that oral rosuvastatin, oral dienogest and intraperitoneal bevacizumab might improve endometriosis in randomly selected female Wistar albino rats with surgically endometriotic implants. Thirty female Wistar albino rats with surgically endometriotic implants were randomized into three treatment groups: oral rosuvastatin (20 mg kg/day; oral rosuvastatin group 1; n = 10), oral progesterone (dienogest group 2; n = 10) and intraperitoneal bevacizumab (2.5 mg/kg of single intraperitoneal injection of bevacizumab; bevacizumab group 3; n = 10), for 10 days. Post-treatment variables were compared. The oral rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than the oral progesterone group (both, p  0.017). Endometrial thickness values and uterine volume values were more significantly reduced in the oral rosuvastatin group than the oral progesterone group (both, p  0.017). In conclusion, oral rosuvastatin and intraperitoneal injection of bevacizumab may cause more significant regression of surgically endometriotic implants in rats than oral progesterone medications.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiogenesis Inhibitors Bevacizumab Endometriosis Hydroxymethylglutaryl-CoA Reductase Inhibitors Nandrolone Rosuvastatin Calcium Angiogenesis Inhibitors Angiogenesis Inhibitors Animals Animals Bevacizumab Bevacizumab Drug Evaluation, Preclinical Drug Evaluation, Preclinical Endometriosis Endometriosis Female Female Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

Cited by (6)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:19:42.633400+00:00
License: CC0 · commercial use OK